FIRST-LINE TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) VERSUS CYTOTOXIC CHEMOTHERAPY IN PATIENTS WITH SENSITISING EGFR MUTATION-POSITIVE ADVANCED LUNG ADENOCARCINOMA: Abstract ID – 210


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles